What Can History Teach Us About Carrizo Oil & Gas Inc. (CRZO) and Protalix BioTherapeutics Inc. (PLX)?

On Sep 16, JOHNSON S P IV, President and CEO sold 8,000 shares of Carrizo Oil & Gas Inc. (NASDAQ: CRZO), with the average selling price of the stock being $9.83 per share. The total amount realized from this sold $78,623. A document was filed with the Securities and Exchange Commission to notify the public about the sold of the shares.

In addition to that, President and CEO – JOHNSON S P IV sold an extra 8,000 shares of this stock in a transaction that took place a day before, on Aug 15, with a share sold at an average of $8.26 and a total of $66,116 was realized from this transaction. After the transaction, the President and CEO – JOHNSON S P IV was left with 179,221 shares of the company’s stock, which is currently worth around $1480365.46.

The recent price movement of CRZO means that it is now down by -66.29% from its 52-week high and 4.18% up against its 52-week low prices. Over the past one week, the price volatility of CRZO stands at 6.42% while the volatility over the past one month is 6.34%. The beta score for this stock is 2.15. A beta score below 1 means that the stock has a low volatility while above 1 signifies that a stock is highly volatile at that particular moment, a data that traders use to keep tabs on their investments.

The company on 08/07/2019 published its latest quarterly earnings, with the report showing that the company recorded 0.94 earnings per share (EPS) during that period. This report was above the expectations of analysts of 0.79 by 0.15. The revenue by the firm was 265.79M for the quarter.

The shares of Carrizo Oil & Gas Inc. (CRZO) dropped by -7.66%, leading to a loss of -$0.62 per share, and saw CRZO end the trading session at $7.47 on Friday 10/18/19. CRZO started the trading session at $7.99, before reaching a daily high of $8.15. It wasn’t able to sustain that growth though and soon jumped to hit a daily low of $7.46.

The trading volume on Friday stood at 6622324, which was below the stock’s 3-month average volume of 5.25 million shares, out of a total 88.26M shares. As the price of the stock dipped, the market valuation of the company dropped to 749.17 million.

The shares of Protalix BioTherapeutics Inc. (NYSE: PLX) went down by -7.94% by the end of the recent trading session. This movement saw its price plunge to close at $0.29, which was lower than the previous closing price of $0.31. Over the past one week, the price of PLX has jumped by 61.11%, while it has recorded a gain of 40.10% over the past one month. Its three-month performance saw PLX lose -26.58% while its six-month performance saw it drop by -30.24%. The situation is different though over the past one year, as the stock price went down by -49.25%, while its year-to-date (YTD) price performance slipped by -6.75%. The stock price has gone up by +70.59% compared to its 90-day low, while it is down -38.30% compared to its 90-day high price.

Let’s take a look at its short, medium and long-term indicators. Composite Indicators shows that Trendspotter rated the stock as a Buy. In the short-term, the stock has a 20-day average volume of 1,861,625 shares, with the short-term indicators averagely rating the stock as a 50% Sell. A look at its medium-term indicators reveals that it has a 50-Day average volume of 905,748 shares and the indicators have an average rating of 50% Sell. The last indicators, the long-term see PLX stock with a 100-Day average volume of 643,364 shares, giving it an average rating of 100% Sell. A look at the general picture of all short, medium and long-term indicators leaves PLX with an average rating of 56% Sell.

Several brokerage firms sent out their reports PLX stock not long ago. In its report sent out on April 17, 2017, Rodman & Renshaw lowered its ratings on PLX to a Buy. In an earlier report on April 04, 2016, Rodman & Renshaw Initiated the stock to a Buy. Jefferies meanwhile in its report on April 23, 2015 Upgrade its rating of the stock from a “Buy” to “Buy”.

In related news to the company’s stock, around 9.70% shares are being held by institutional investors. In a recent SEC filing, the company revealed that 39 institutions currently hold the PLX stock. In the last quarter, a 12,446,992 PLX shares were in the possession of institutions. On the other hand, the company recorded 6 new institutions who bought it their stock, while 8 institutions sold their entire PLX reserve. Of the current institutions investing in the stock, 13 increased their investment while 11 decreased their investment in the stock.